Novocure's Tumor Treating Fields improves quality of life in Phase 3 pancreatic cancer trial
NVCR•Novocure said published Phase 3 PANOVA-3 results showed quality-of-life and pain benefits from Tumor Treating Fields with chemotherapy for unresectable, locally advanced pancreatic cancer. The combination improved overall survival versus chemotherapy alone, meeting the trial’s primary endpoint.
1. Trial results
Published PANOVA-3 results in JAMA Network Open showed quality-of-life and pain benefits from Tumor Treating Fields combined with gemcitabine and nab-paclitaxel as first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. The combination improved overall survival versus chemotherapy alone, meeting the trial’s primary endpoint.
2. Safety findings
No new safety signals emerged. Mild to moderate skin reactions were the most common device-related adverse events.
